During the past 2 decades, life-course social-ecological frameworks have emerged across health, developmental, social, behavioral, and public health disciplines as useful models for explaining how health trajectories develop over an individual's lifetime and how this knowledge can guide and inform new approaches to clinical and public health practice, multilevel policies, and research. Viewed from this perspective, and with emphasis on global cardiovascular health promotion and prevention of cardiovascular disease (CVD), this article summarizes evidence on the early origins and progression of CVD processes across the life course of individuals and diverse populations. Current evidence-based guidelines for CVD prevention are summarized, and recommendations for future research are suggested.
Halfon N,Holstein M.Life course health development: an integrated framework for developing health, policy and research Milbank Q. 2002;80 (3): 433-479
2.
Ben-Shlomo Y,Kuh D.A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives Int J Epidemiol. 2002;31 (2): 285-293
3.
Kavey RE,Daniels SR,Lauer RM,Atkins DL,Hayman LL,Taubert K.American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood Circulation. 2003;107 (4): 1562-1566
4.
Daniels SR,Greer FR.Lipid screening and cardiovascular health in childhood Pediatrics. 2008;122 (1): 198-208
5.
Gidding SS,Lichtenstein AH,Faith MS.Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research Circulation. 2009;119:1161-1175
6.
Berenson GS,Srinivasan SR,Bao W.Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study N Engl J Med. 1998;338 (23): 1650-1656
7.
McGill HC,McMahan CA,Malcom GT,Oalmann MC,Strong JP.Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth Arterioscler Thromb Vase Biol. 1995;15 (9): 512-1531
8.
McGill HC,McMahan CA,Malcom GT,Oalmann MC,Strong JP.Relation of glycohemoglobin and adiposity to atherosclerosis in youth Arterioscler Thromb Vase Biol. 1995;15:431-440
9.
Davis PH,Dawson JD,Riley WA,Lauer RM.Carotid intimal-media thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study Circulation. 2001;104:2815-2819
10.
Li S,Chen W,Srinivasan SR.Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study JAMA. 2003;290 (17): 2271-2276
11.
Raitakari OT,Juonala M,Kahonen M.Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study JAMA. 2003;290 (17): 2277-2283
12.
Urbina EM,Kimball TR,McCoy CE,Khoury PR,Daniels SR,Dolan LM.Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function Circulation. 2009;119 (22): 2913-2919
13.
Lauer RM,Clarke WR.Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia: the Muscatine Study JAMA. 1990;264 (23): 3034-3038
14.
Webber LS,Srinivasan SR,Wattigney WA,Berenson GS.Tracking of serum lipids and lipoproteins from childhood to adulthood; the Bogalusa Heart Study Am J Epidemiol. 1991;133 (9): 884-899
15.
Riddoch C,Edwards D,Page A.The European Youth Heart Study. Cardiovascular disease risk factors in children: rationale, aims, design, and validation of methods J Phys Act Health. 2005;2:115-129
16.
Porkka KV,Viikari JS,Taimela S,Dahl M,Akerblom HK.Tracking and predictiveness of serum lipid and lipoproteins measurements in childhood: a 12-year follow-up: the Cardiovascular Risk in Young Finns study Am J Epidemiol. 1994;140 (12): 1096-1110
17.
Lee DS,Chiu M,Manuel DG.Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors CMAJ. 2009;181 (3–4): E55-E66
18.
Paradis G,Lambert M,O'Loughlin J.The Quebec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth Can J Cardiol. 2003;19 (5): 523-531
19.
Janssen I,Katzmarzyk PT,Boyce WF.Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. The International Association for the Study of Obesity Obes Rev. 2005;6 (2): 123-132
20.
Caprio S,Bronson M,Sherwin RS,Rife F,Tamborlane WV.Coexistence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children Diabetologia. 1996;39 (12): 1489-1497
21.
Fagot-Campagna A,Pettitt DJ,Engelgau MM.Type 2 diabetes among North American children and adolescents: an epidemio-logic review and a public health perspective J Pediatr. 2000;136 (5): 664-672
22.
Gidding SS.Dyslipidemia in the metabolic syndrome in children J Cardiometab Syndr. 2006;1 (4): 282-285
23.
Hansen ML,Gunn PW,Kaelber DC.Underdiagnosis of hypertension in children and adolescents JAMA. 2007;298 (8): 874-879
24.
Steinberger J,Daniels SR,Eckel R.Progress and challenges in the metabolic syndrome in children and adolescents Circulation. 2009;119 (4): 628-647
25.
Lau D,Douketis J,Morrison KM,Hramiak I,Sharma A,Ur E.Expert panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children: summary report CMAJ. 2007;176 (suppl 8): S1-S13
26.
Barlow SE.Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent, overweight and obesity: summary report Pediatrics. 2007;20 (suppl 4): S164-S192
27.
Morrison KM,Atkinson SA,Yusuf S.The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis Am Heart J. 2009;158 (4): 533-539
28.
Olsen J,Melbye M,Olsen SF.The Danish national birth cohort – its background, structure and aim Scand J Public Health. 2001;29 (4): 300-307
29.
Reilly JJ,Armstrong J,Dorosty AR.Early life risk factors for obesity in childhood: cohort study BMJ. 2005;330 (7504): 1357-1364
30.
National Institutes of Health. National Heart, Lung, and Blood Institute. NHLBI Pediatric Guidelines for Cardiovascular Health Promotion and Risk Reduction. 2010. In press.
31.
A Race Against Time. The Challenge of Cardiovascular Disease in Developing Economieshttp://www.earth.columbia.edu/news/2004/images/raceagainsttime_FINAL_051104.pdf Accessed June 18, 2010.
32.
Wilson PW,D'Agostino RB,Levy D,Belanger AM,Silbershatz H,Kannel WB.Prediction of coronary heart disease using risk factor categories Circulation. 1998;97 (18): 1837-1847
33.
GreenbergHRaymondSULeederSRCardiovascular disease and global health: threat and opportunity. Health Affairs Web Exclusive 2005;W5-31-4lhttp://content.healthaffairs.org.ezproxy.lib.umb.edu/cgi/reprint/hlthaff.w5.31vl Accessed June 20, 2010.
34.
Reddy KS.India wakes up to the threat of cardiovascular diseases J Am Coll Cardiol. 2007;50 (14): 1370-1372
35.
Heart disease and stroke statistics: 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation. 2009;119 (3): e21-e81
36.
Grundy SM,Cleeman JI,Merz CNB.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation. 2004;110 (2): 227-239
37.
Nakamura H,Arakawa K,Itakura H.Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial Lancet. 2006;368 (9540): 1155-1163
38.
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials Lancet. 2000;356 (9246): 1955-1964
39.
World Population Prospects: The 2002 Revision (Medium Scenario). New York, NY: United Nations Publication; 2003:
40.
World Population Prospects: The 2004 Revision. United Nations Publication; 2005:
41.
Population Challenges and Development Goals. United Nations Publication; 2005:
42.
UN Secretariat. The Diversity of Changing Population Age Structures in the World. New York, NY: Department of Economic and Social Affairs Population Division; 2005:
43.
Population Reference Bureau StaffPopul Bull200459
44.
The impact of cardiovascular risk factors on the age-related excess of coronary heart disease Int J Epidemiol. 2006;35 (4): 1025-1033
45.
Martiniuk AL,Lee CM,Lawes CM.Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region J Hypertens. 2007;25 (l): 73-79
46.
Sasayama S.Heart disease in Asia Circulation. 2008;118:2669-2671
47.
Ford ES,Giles WH,Dietz WH.Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey JAMA. 2002;287 (3): 356-359
48.
Vita AJ,Terry RB,Hubert HB,Fries JF.Aging, health risks, and cumulative disability N Engl J Med. 1998;338 (15): 1035-1041
49.
Gill TM,Baker DI,Gottschalk M,Gahabuer EA,Charpentier PA,de Regt PT.A rehabilitation program for physically frail community-living older persons Arch Phys Med Rehabil. 2003;84 (3): 394-404
50.
Preis SR,Hwang SJ,Coady S.Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes meilitus in the Framingham Heart Study, 1950 to 2005 Circulation. 2009;119 (13): 1728-1735
51.
Miettinen TA,Pyorala K,Olsson AG.Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the 4S study Circulation. 1997;96 (12): 4211-4218
52.
LaRosa JC,He J,Vupputuri S.Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA. 1999;282 (24): 2340-2346
53.
Lewis SJ,Moye LA,Sacks FM.Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events Trial (CARE) Ann Intern Med. 1998;129 (9): 681-689
54.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med. 1998;339 (19): 1349-1357
55.
Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med. 2002;346 (6): 393-403
56.
Yusuf S,Hawken S,Óunpuu S.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study Lancet. 2004;364 (9438): 937-952
57.
Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region Circulation. 2005;112 (22): 3384-3390
58.
de Ruijter W,Westendorp RG,Assendelft WJ.Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study BMJ. 2008;337:a3083
59.
Williams MA,Heg JL,Ades PA.Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >75 years of age) Circulation. 2002;105 (14): 1735-1743
60.
Shepherd J,Blauw GJ,Murphy MB.Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial Lancet. 2002;360 (9346): 1623-1630
61.
Beckett NS,Peters R,Fletcher AE.Treatment of hypertension in patients 80 years of age or older N Engl J Med. 2008;358 (18): 1887-1898
62.
Pearson TA,Blair SN,Daniels SR.AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases Circulation. 2002;106 (3): 388-391
63.
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart. 2005;91 (suppl V): v1-v52
64.
Lloyd-Jones DM.Cardiovascular risk prediction: basic concepts, current status and future directions Circulation. 2010;121:1768-1777
65.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation. 2002;106 (25): 3143-3421
66.
D'Agostino RB,Grundy SM,Sullivan LM,Wilson P.Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation JAMA. 2001;286:180-187
67.
Brindle P,May M,Gill P.Primary prevention of cardiovascular disease: a Web-based risk score for seven British black and minority ethnic groups Heart. 2006;92 (11): 1595-1602
68.
D'Agostino RB,Vasan RS,Pencina MJ.General cardiovascular risk profile for use in primary care. The Framingham Heart Study Circulation. 2008;117 (6): 743-753
69.
Assmann G,Cullen P,Schulte H.Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow up of the Prospective Cardiovascular Munster (PROCAM) study Circulation. 2002;105:310-315
70.
Hippisley-Cox J,Coupland C,Vinogradova Y,Robson J,May M,Brindle P.Derivation and validation of QRISK a new cardiovascular risk score for the United Kingdom: prospective open cohort study BMJ. 2007;335 (7611): 136
71.
Ridker PM,Buring JE,Rifai N,Cook NR.Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score JAMA. 2007;297:611-619
72.
Ridker PM,Paynter NP,Rifai N,Gaziano JM,Cook NR.C-reactive protein and parental history improve global risk prediction: the Reynolds score for men Circulation. 2008;118:2243-2251
73.
New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners. 2nd ed.Wellington, New Zealand: New Zealand Guidelines Group; 2009:
74.
Conroy RM,Pyorala K,Fitzgerald AP.Estimation of ten year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J. 2003;24 (11): 987-1003
75.
Lloyd-Jones DM,Wilson PWF,Larson MG.Framingham Risk Score and prediction of lifetime risk for coronary heart disease Am J Cardiol. 2004;94 (l): 20-24
Lloyd-Jones DM,Leip EP,Larson MG.Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation. 2006;113 (6): 791-798
78.
Smith SC,Allen J,Blair SN.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update Circulation. 2006;113 (19): 2363-2372
79.
Mosca L,Benjamin E,Berra K.Evidence-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association, [published online ahead of print February 16, 2011] Circulation. 2011;123:1243-1262
